Pear Therapeutics Inc. (PEARQ)
OTCMKTS: PEARQ · Delayed Price · USD
0.00
0.00 (0.00%)
Apr 30, 2024, 4:00 PM EDT - Market closed
Pear Therapeutics Revenue
In the year 2022, Pear Therapeutics had annual revenue of $12.69M with 201.66% growth. Revenue in the quarter ending December 31, 2022 was $2.57M with 94.32% year-over-year growth.
Revenue (ttm)
$12.69M
Revenue Growth
+201.66%
P/S Ratio
0.00
Revenue / Employee
$63,470
Employees
200
Market Cap
142.00 USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2022 | 12.69M | 8.49M | 201.66% |
Dec 31, 2021 | 4.21M | -5.18M | -55.16% |
Dec 31, 2020 | 9.38M | -23.18M | -71.18% |
Dec 31, 2019 | 32.56M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionPEARQ News
- 11 months ago - Nox Health Closes Acquisition of Somryst, the Only FDA-Cleared Digital Insomnia Treatment, From Pear Therapeutics - GlobeNewsWire
- 1 year ago - Pear Therapeutics Files for Chapter 11 and Will Seek to Sell Assets Through Sales Process - Business Wire
- 1 year ago - Pear Therapeutics Announces Process Exploring Strategic Alternatives - Business Wire
- 1 year ago - Pear Therapeutics to Participate in 43rd Annual Cowen Healthcare Conference - Business Wire
- 1 year ago - Pear Therapeutics to Participate in the 2023 BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference - Business Wire
- 1 year ago - Pear Therapeutics and BrightView Health Expand Pilot Program to Provide Prescription Digital Therapeutics for the Treatment of Substance Use Disorders - Business Wire
- 1 year ago - Pear Therapeutics Announces Inclusion of reSET® and reSET-O® on the January 2023 Florida Medicaid Preferred Drug List - Business Wire
- 1 year ago - Pear Therapeutics to Participate in Citi's BioTech C-Suite Virtual Fireside Chat Series - Business Wire